Biomarkers—A General Review

Jeffrey K. Aronson1, Robin E. Ferner2

1 Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, Radcliffe Infirmary, Oxford, 2 School of Medicine, University of Birmingham, Birmingham
Publication Name:  Current Protocols in Pharmacology
Unit Number:  Unit 9.23
DOI:  10.1002/cpph.19
Online Posting Date:  March, 2017
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

A biomarker is a biological observation that substitutes for and ideally predicts a clinically relevant endpoint or intermediate outcome that is more difficult to observe. The use of clinical biomarkers is easier and less expensive than direct measurement of the final clinical endpoint, and biomarkers are usually measured over a shorter time span. They can be used in disease screening, diagnosis, characterization, and monitoring; as prognostic indicators; for developing individualized therapeutic interventions; for predicting and treating adverse drug reactions; for identifying cell types; and for pharmacodynamic and dose‐response studies. To understand the value of a biomarker, it is necessary to know the pathophysiological relationship between the biomarker and the relevant clinical endpoint. Good biomarkers should be measurable with little or no variability, should have a sizeable signal to noise ratio, and should change promptly and reliably in response to changes in the condition or its therapy. © 2017 by John Wiley & Sons, Inc.

Keywords: adverse drug reactions; biomarkers; drug discovery; drug development; diagnosis; monitoring drug therapy; screening; surrogate endpoints; surrogate markers

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • History
  • Definitions
  • Advantages of Biomarkers
  • Uses of Biomarkers
  • Taxonomies of Biomarkers
  • Criteria for Useful Biomarkers
  • Identifying Biomarkers
  • Validation of Biomarkers
  • Pitfalls and Problems Associated with the use of Biomarkers
  • Choosing the Best Biomarker Test
  • Practical Matters
  • A Proposed Definition
  • Conclusions
  • Literature Cited
  • Figures
  • Tables
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
  Aronson, J. K. (2005). Biomarkers and surrogate endpoints. British Journal of Clinical Pharmacology, 59, 491‐494. doi: 10.1111/j.1365‐2125.2005.02435.x.
  Aronson, J. K. (2008). Biomarkers and surrogate endpoints in monitoring therapeutic interventions. In P. Glasziou, L. Irwig, & J. K. Aronson (Eds.), Evidence‐based medical monitoring: From principles to practice (pp. 48‐62). Oxford: Blackwell Publishing.
  Aronson, J. K. (2012). An agenda for UK clinical pharmacology: Research priorities in biomarkers and surrogate endpoints. British Journal of Clinical Pharmacology, 73, 900‐907. doi: 10.1111/j.1365‐2125.2012.04234.x.
  Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics, 69, 89‐95. doi: 10.1067/mcp.2001.113989.
  Burnett, H. F., Tanoshima, R., Chandranipapongse, W., Madadi, P., Ito, S., & Ungar, W. J. (2014). Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: A systematic review of clinical guidance documents. The Pharmacogenomics Journal, 14, 493‐502. doi: 10.1038/tpj.2014.47.
  Buyse, M., Molenberghs, G., Paoletti, X., Oba, K., Alonso, A., Van der Elst, W., & Burzykowski, T. (2016). Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. Biometrical Journal, 58, 104‐132. doi: 10.1002/bimj.201400049.
  Callisaya, M. L., Sharman, J. E., Close, J., Lord, S. R., & Srikanth, V. K. (2014). Greater daily defined dose of antihypertensive medication increases the risk of falls in older people—A population‐based study. Journal of the American Geriatrics Society, 62, 1527‐1533. doi: 10.1111/jgs.12925.
  Cardiac Arrhythmia Suppression Trial Investigators. (1989). Preliminary report: Effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. The New England Journal of Medicine, 321, 406‐412. doi: 10.1056/NEJM198908103210629.
  Carr, E. A., Jr. (1946). A rapid bedside test for the detection of hypoglycemia. Journal of Laboratory and Clinical Medicine, 31, 1267‐1269.
  Cohn, J. (1991). Lessons from V‐HeFT: Questions for V‐HeFT11 and the future therapy of heart failure. Herz, 16, 267‐271.
  Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies, Board on Health Care Services, Institute of Medicine, National Academies of Sciences, Engineering, and Medicine. (2016). In L. A. Graig, J. K. Phillips, & H. L. Moses (Eds.), Biomarker tests for molecularly targeted therapies: Key to unlocking precision medicine. Washington, DC: National Academies Press.
  Department of Health and Human Services. Food and Drug Administration. (1992). New drug, antibiotic and biological drug product regulations: Accelerated approval. Proposed Rule 57. Federal Register 13234‐13242.
  Drancourt, M., Michel‐Lepage, A., Boyer, S., & Raoult, D. (2016). The point‐of‐care laboratory in clinical microbiology. Clinical Microbiology Reviews, 29, 429‐447. doi: 10.1128/CMR.00090‐15.
  Engelen, M. J., de Bruijn, H. W., Hollema, H., ten Hoor, K. A., Willemse, P. H., Aalders, J. G., & van der Zee, A. G. (2000). Serum CA 125, carcinoembryonic antigen, and CA 19‐9 as tumor markers in borderline ovarian tumors. Gynecologic Oncology, 78, 16‐20. doi: 10.1006/gyno.2000.5811.
  Epstein, A. E., Hallstrom, A. P., Rogers, W. J., Liebson, P. R., Seals, A. A., Anderson, J. L., Cohen, J. D., Capone, R. J., & Wyse, D. G. (1993). Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA, 270, 2451‐2455. doi: 10.1001/jama.1993.03510200057032.
  Ferner, R. E., Dear, J. W., & Bateman, D. N. (2011). Management of paracetamol poisoning. BMJ, 342, d2218. doi: 10.1136/bmj.d2218.
  FitzGerald, G. A. (2016). Measure for measure: Biomarker standards and transparency. Science Translational Medicine, 8, 343fs10. doi: 10.1126/scitranslmed.aaf8590.
  Friedman, L. M., Furberg, C. D., & De Mets, D. L. (1985). Fundamentals of clinical trials. 2nd edition. Littleton, MA: PSG Publications Company.
  Gargano, G., Correale, M., Abbate, I., Falco, G., De Frenza, N., Lorusso, V., De Lena, M., & De Leonardis, A. (1990). The role of tumour markers in ovarian cancer. Clinical and Experimental Obstetrics & Gynecology, 17, 23‐29.
  Gilbert, R., Salanti, G., Harden, M., & See, S. (2005). Infant sleeping position and the sudden infant death syndrome: Systematic review of observational studies and historical review of recommendations from 1940 to 2002. International Journal of Epidemiology, 34, 874‐887. doi: 10.1093/ije/dyi088.
  Gion, M., & Daidone, M. G. (2004). Circulating biomarkers from tumour bulk to tumour machinery: Promises and pitfalls. European Journal of Cancer, 40, 2613‐2622. doi: 10.1016/j.ejca.2004.07.031.
  Higgs, C. M. B., & Laszlo, G. (1996). Influence of treatment with beclomethasone, cromoglycate and theophylline on perception of bronchoconstriction in patients with bronchial asthma. Clinical Science, 90, 227‐234. doi: 10.1042/cs0900227.
  Howick, J., Glasziou, P., & Aronson, J. K. (2009). The evolution of evidence hierarchies: What can Bradford Hill's ‘guidelines for causation’ contribute? Journal of the Royal Society of Medicine, 102, 186‐194. doi: 10.1258/jrsm.2009.090020.
  Ingram, D. K., Nakamura, E., Smucny, D., Roth, G. S., & Lane, M. A. (2001). Strategy for identifying biomarkers of aging in long‐lived species. Experimental Gerontology, 36, 1025‐1034. doi: 10.1016/S0531‐5565(01)00110‐3.
  Irwig, L., & Glasziou, P. (2008). Choosing the best monitoring tests. In P. Glasziou, L. Irwig, J. K. Aronson (Eds.) Evidence‐based medical monitoring: From principles to practice (pp. 63‐74). Oxford: Blackwell Publishing.
  Joller‐Jemelka, H. I., Vogt, M., & Joller, P. W. (1985). Immunologische Laboruntersuchungen bei Patienten mit erworbenem Immunmangel‐syndrom (AIDS) und bei AIDS‐Verdacht. [Immunologic laboratory tests in acquired immunodeficiency syndrome (AIDS) and suspected AIDS]. Schweizerische Medizinische Wochenschrift, 115, 125‐132.
  Jortani, S. A., Prabhu, S. D., & Valdes, R. Jr. (2004). Strategies for developing biomarkers of heart failure. Clinical Chemistry, 50, 265‐278. doi: 10.1373/clinchem.2003.027557.
  Karagiannis, A. K., Girio‐Fragkoulakis, C., & Nakouti, T. (2016). Procalcitonin: A new biomarker for medullary thyroid cancer? A systematic review. Anticancer Research, 36, 3803‐3810.
  Li, S., Yang, X., Yang, J., Zhen, J., & Zhang D. (2016). Serum microRNA‐21 as a potential diagnostic biomarker for breast cancer: A systematic review and meta‐analysis. Clinical and Experimental Medicine, 16, 29‐35. doi: 10.1007/s10238‐014‐0332‐3.
  Li, T., Zheng, Y., Sun, H., Zhuang, R., Liu, J., Liu, T., & Cai, W. (2016). K‐Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: A systematic review with meta‐analysis. Medical Oncology, 33, 61. doi: 10.1007/s12032‐016‐0777‐1.
  Lopez‐Barbosa, N., Gamarra, J. D., & Osma, J. F. (2016). The future point‐of‐care detection of disease and its data capture and handling. Analytical and Bioanalytical Chemistry, 408, 2827‐2837. doi: 10.1007/s00216‐015‐9249‐2.
  Mundkur, B. D. (1949). Evidence excluding mutations, polysomy, and polyploidy as possible causes of non‐Mendelian segregations in Saccharomyces. Annals of the Missouri Botanical Garden, 36, 259‐280. doi: 10.2307/2394394.
  National Committee for the Evaluation of Centoxin. (1994). The French National Registry of HA‐1A (Centoxin) in septic shock. A cohort study of 600 patients. Archives of Internal Medicine, 154, 2484‐2491. doi: 10.1001/archinte.1994.00420210124014.
  NIH Definitions Working Group. (2000). Biomarkers and surrogate endpoints in clinical research: Definitions and conceptual model. In G. J. Downing (Ed.), Biomarkers and Surrogate Endpoints (pp. 1‐9). Amsterdam: Elsevier.
  Order, S. E. (1977). Beneficial and detrimental effects of therapy on immunity in breast cancer. International Journal of Radiation Oncology, 2, 377‐380. doi: 10.1016/0360‐3016(77)90101‐8.
  Oxford English Dictionary online. (2016). “surrogate, n. and adj”. Oxford: Oxford University Press.
  Pearson, C. E. (2011). Repeat associated non‐ATG translation initiation: One DNA, two transcripts, seven reading frames, potentially nine toxic entities! PLoS Genetics, 7, e1002018. doi: 10.1371/journal.pgen.1002018.
  Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T….Wadelius, M. (2013). A randomized trial of genotype‐guided dosing of warfarin. The New England Journal of Medicine, 369, 2294–2303. doi: 10.1056/NEJMoa1311386.
  Porter, K. A. (1957). Effect of homologous bone marrow injections in X‐irradiated rabbits. British Journal of Experimental Pathology, 38, 401‐412.
  Reynolds, D. J., & Aronson J. K. (1992). ABC of monitoring drug therapy. Cyclosporin. BMJ, 305, 1491‐1494. doi: 10.1136/bmj.305.6867.1491.
  Rho, J. H., Bauman, A. J., Boettger, H. G., & Yen, T. F. (1973). A search for porphyrin biomarkers in Nonesuch Shale and extraterrestrial samples. Space Life Sciences, 4, 69‐77. doi: 10.1007/BF02626343.
  Shubik, M. (1983). The strategic audit: A game theoretic approach to corporate competitive strategy. Managerial Decision Economics, 4, 160‐161. doi: 10.1002/mde.4090040306.
  Steinitz, K. (1947). A simple bedside test for renal function; the semiquantitative determination of blood creatinine. Harefuah, 32, 174.
  Tian, T., Li, J., Song, Y., Zhou, L., Zhu, Z., & Yang, C. J. (2016). Distance‐based microfluidic quantitative detection methods for point‐of‐care testing. Lab on a Chip, 16, 1139‐1151. doi: 10.1039/C5LC01562F.
  Wald, N. J, Hacksaw, A. K., & Frost, C. D. (1999). When can a risk factor be used as a worthwhile screening test? British Journal of Medicine, 319, 1562‐1565. doi: 10.1136/bmj.319.7224.1562.
  Weatherall, M., Ioannides, S., Braithwaite, I., & Beasley, R. (2015). The association between paracetamol use and asthma: Causation or coincidence? Clinical & Experimental Allergy, 45, 108‐113. doi: 10.1111/cea.12410.
  Wittes, J., Lakatos, E., & Probstfield, J. (1989). Surrogate endpoints in clinical trials: Cardiovascular diseases. Statistics in Medicine, 8, 415‐425. doi: 10.1002/sim.4780080405.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library